Abstract
With the discovery of RNA interference technology, small-interfering RNA (siRNA) has emerged as new powerful tool for gene therapy because of its high targeting specificity and selectivity. However, one of the limitations to successful gene therapy is the inability to monitor delivery of genes and therapeutic responses at the targeted site. Hence, a combinatorial approach of gene therapy with molecular imaging has been crucial in optimizing gene therapy. Recent advances in nanotechnology have made tremendous efforts to develop multifunctional nanoparticles that contain imaging and therapeutic agents together for image-guided therapy. The nanoparticles serve as contrast agents in imaging for disease detection with simultaneous delivery of therapeutics to cure the diseases. The therapy also helps to monitor the drug accumulation and assimilation in the body, thereby facilitating the evaluation of treatment effects. Here, we present an overview of polymer and lipid-based carriers for siRNA delivery, along with imaging agents as imageguided therapy, in the treatment of breast, lung, liver, ovarian, cervical, and prostate cancers.
Keywords: RNA interference, gene therapy, nanotechnology, imaging agents, cancer theragnosis.
Current Pharmaceutical Design
Title:Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy
Volume: 21 Issue: 31
Author(s): Yong-Dong Kim, Tae-Eun Park, Bijay Singh, Sushila Maharjan, Kye-Soo Cho, Kyoung Pyo Park, Yun-Jaie Choi, Rohidas B. Arote and Chong-Su Cho
Affiliation:
Keywords: RNA interference, gene therapy, nanotechnology, imaging agents, cancer theragnosis.
Abstract: With the discovery of RNA interference technology, small-interfering RNA (siRNA) has emerged as new powerful tool for gene therapy because of its high targeting specificity and selectivity. However, one of the limitations to successful gene therapy is the inability to monitor delivery of genes and therapeutic responses at the targeted site. Hence, a combinatorial approach of gene therapy with molecular imaging has been crucial in optimizing gene therapy. Recent advances in nanotechnology have made tremendous efforts to develop multifunctional nanoparticles that contain imaging and therapeutic agents together for image-guided therapy. The nanoparticles serve as contrast agents in imaging for disease detection with simultaneous delivery of therapeutics to cure the diseases. The therapy also helps to monitor the drug accumulation and assimilation in the body, thereby facilitating the evaluation of treatment effects. Here, we present an overview of polymer and lipid-based carriers for siRNA delivery, along with imaging agents as imageguided therapy, in the treatment of breast, lung, liver, ovarian, cervical, and prostate cancers.
Export Options
About this article
Cite this article as:
Kim Yong-Dong, Park Tae-Eun, Singh Bijay, Maharjan Sushila, Cho Kye-Soo, Park Pyo Kyoung, Choi Yun-Jaie, Arote B. Rohidas and Cho Chong-Su, Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013192327
DOI https://dx.doi.org/10.2174/138161282131151013192327 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rational Drug Development Using Gene-Targeted Agents and Their Application in Anti-Gene Radiotherapy
Current Genomics Bioluminescent Proteins Prediction with Voting Strategy
Current Bioinformatics Novel N-Substituted Thiazolidinones as Proton Pump Inhibitors and Potent Anti-Ulcer Agents: SAR Study
Letters in Drug Design & Discovery Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Pathophysiological Role of Hepatocyte Nuclear Factor 6 in Negative Regulation of Hepatic Apoptosis: A Novel Hypothesis
Current Molecular Medicine The Use of SIFT-MS in Profiling the Faecal Volatile Metabolome in Horses with Colic: A Pilot Study
Current Analytical Chemistry Synthesis and Antitumor Invasive Activity of Novel Ionone Alkaloid Derivatives
Letters in Drug Design & Discovery Drug Repositioning Through Network Pharmacology
Current Topics in Medicinal Chemistry Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants
Mini-Reviews in Medicinal Chemistry Targeted Drug Delivery Systems for Lung Macrophages
Current Drug Targets Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs
Current Pharmaceutical Design The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Dutasteride in Androgenetic Alopecia: An Update
Current Clinical Pharmacology Treatment of Atopic Dermatitis: Current Status and Future Prospects
Current Drug Therapy CoMFA/CoMSIA and Molecular Docking Studies of Novel Matrix Metalloproteinase- 2 Inhibitors Based on L-tyrosine Scaffold
Letters in Drug Design & Discovery